Very light on the details, sadly. Even WP, typically a good talker, was finding it hard to make the ends meet on this one.
He knows what is coming from this. Here's how I am seeing it, and thought about before this, that the study was poorly formed and not large enough to draw conclusions. Poor form on the transparency with regards to the rest of the program though. Sounds like the collaboration is with one oncologist somewhere with some patients, not much else.
Not the decisive action one would have desired. I vote (not that it counts for much) to divest the immunotherapies arm ASAP.
Ann: Admedus Releases Results of HSV-2 Phase IIa Study, page-34
-
- There are more pages in this discussion • 317 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.30 |
Change
0.150(0.99%) |
Mkt cap ! $294.1M | |||
| Open | High | Low | Value | Volume |
| $15.35 | $15.35 | $15.00 | $92.29K | 6.09K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 50 | $15.20 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.30 | 276 | 1 |
View Market Depth
| Last trade - 16.10pm 31/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |